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• Population: Patients effected with PE
• Intervention: Prophylactic use of LMWH
• Comparison: Prophylactic use of UFH
• Outcome: decrease in the morbidity and mortality 
of PE
• Timeline: During time of prophylaxis of PE
Purpose
• Unfractionated Heparin (UFH)
• A Standard dose of UFH consists of an IV bolus of 
80U/kg followed by a continuous infusion of 
18U/kg/hr.
• Low Molecular Weight Heparin (LMWH)
• There are many different compounds of LMWH, but 
the most common ones used are Enoxaparin Sodium, 
Dalteparin Sodium, and Tinzaparin Sodium. Below, 
you can see the typical dosing for each.
• LMWH dosage is determined by weight, therefore it 
can be administered in the out-patient setting
• Both LMWH and UFH require 5-7 initial days of warfarin 
therapy, with a therapeutic INR goal of 2-3 and aPTT goal of 
1.5-2.5x control value. Once these lab values are reached, the 
patient is on P.O therapy for 3-6 months, depending on the 




• UFH and LMWH both decrease the risk of PE with no 
significant difference in prophylaxis
• LMWH decreases the risk of major hemorrhage by 52% 
compared to UFH.
• Shorter hospital stays are associated with the use of LMWH 
because home therapy is an option
• The overall cost of LMWH is less than UFH that could 
potentially save the U.S. $250 million a year.
Conclusion
• Overall, the use of LMWH is proven to be more 
beneficial than the use of UFH in PE prophylaxis. 
• There are several advantages including a decrease in the 
risk of heparin induced thrombocytopenia and hospital 
length of stay.
• Because LMWH is an effective home therapy due to its 
consistent effects, it eliminates the need for intense lab 
monitoring of aPTT and INR values. 
Prophylactic Use of LMWH vs UFH in PE Patients
Kyleigh Grieshaber, Senior BSN Student 
Pittsburg State University, Irene Ransom Bradley School of Nursing
Research Colloquium 2019
Gaps in the Literature
• Larger, more diverse sample size was needed in the 
article discussing the new JFK Risk Assessment tool. 
• Some studies suggested different time frames for long 
term anticoagulant use, regardless of the use of UFH or 
LMWH.
• Dosage recommendations for UFH and LMWH 
fluctuated.
• Overall, the population size was good, validity and 
reliability were tested in all research studies use in this 
review of literature. 
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• Pulmonary Embolism (PE) is the third 
leading cause of cardiovascular death in the 
United States with at least 950,000 deaths 
annually. 
• PE is the most preventable cause of 
unexpected deaths in hospitalized patients,
however, it is the most common.
• 50-80% of these cases are asymptomatic, 
with 70% of these cases going undetected 
until it’s too late. 
• Virchow’s Triad identifies the three major 
underlying factors that contribute to PE
• Stasis (changes in blood flow pattern)
• Injury (changes in blood vessel wall)
• Hypercoagulability (change in 
consistency of blood)
• Risk Factors include:









The purpose of this review of literature was to compare 
the efficacy, safety, and cost of LMWH with UFH and 
make decisions about selecting the best prophylactic 
therapy for PE patients. 
• Signs and Symptoms
• Redness
• Swelling
• Rash
• Hypotension
• Dyspnea
• Tachycardia
• Chest 
discomfort
• Hypoxemia
• Respiratory 
arrest
• death
